Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO

Documenti analoghi

• Risk of harlequin syndrome during bi-femoral peripheral VA-ECMO: should we pay more attention to the watershed or try to change the venous cannulation site?
  di: Honore, Patrick M., et al.
  Pubblicazione: (2020)
• 500 mg as bolus followed by an extended infusion of 1500 mg of meropenem every 8 h failed to achieve in one-third of the patients an optimal PK/PD against non-resistant strains of these organisms: is CRRT responsible for this situation?
  di: Honore, Patrick M., et al.
  Pubblicazione: (2020)
• Using indirect calorimetry in place of fixed energy prescription was feasible and energy targets were more closely met: do not forget an important limitation
  di: Patrick M. Honore, et al.
  Pubblicazione: (2020-06-01)
• Early latency evoked potentials can no longer be considered an infallible predictor of neurologic outcome
  di: Patrick M. Honore, et al.
  Pubblicazione: (2020-06-01)
• Plasma exchange in critically ill COVID-19 patients improved inflammation, microcirculatory clot formation, and hypotension, thereby improving clinical outcomes: fact or fiction?
  di: Patrick M. Honore, et al.
  Pubblicazione: (2020-09-01)